147 related articles for article (PubMed ID: 18714439)
1. Quest for cystic fibrosis pharmacotherapy.
Joo NS
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):861-2. PubMed ID: 18714439
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
3. Drug bests cystic-fibrosis mutation.
Ledford H
Nature; 2012 Feb; 482(7384):145. PubMed ID: 22318583
[No Abstract] [Full Text] [Related]
4. Novel pharmacologic therapies for cystic fibrosis.
Zeitlin PL
J Clin Invest; 1999 Feb; 103(4):447-52. PubMed ID: 10021451
[No Abstract] [Full Text] [Related]
5. CFTR mutations and cystic fibrosis.
Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
[No Abstract] [Full Text] [Related]
6. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
7. Nonstop treatment of cystic fibrosis.
Dietz HC; Hamosh A
Nat Med; 1996 Jun; 2(6):608-9. PubMed ID: 8640540
[No Abstract] [Full Text] [Related]
8. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.
Gelman MS; Kopito RR
J Clin Invest; 2002 Dec; 110(11):1591-7. PubMed ID: 12464661
[No Abstract] [Full Text] [Related]
9. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
10. [Modifier genes and cystic fibrosis].
Corvol H; Flamant C; Vallet C; Clement A; Brouard J
Arch Pediatr; 2006 Jan; 13(1):57-63. PubMed ID: 16274977
[TBL] [Abstract][Full Text] [Related]
11. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
12. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
[No Abstract] [Full Text] [Related]
13. Cystic fibrosis: CFTR modulators and their mechanism of action.
Nieddu E
Curr Pharm Des; 2013; 19(19):3474-5. PubMed ID: 23331031
[No Abstract] [Full Text] [Related]
14. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
15. Targeting nonsense-mediated cystic fibrosis: is it premature to stop now?
O'Sullivan BP
Lancet Respir Med; 2014 Jul; 2(7):509-11. PubMed ID: 24836206
[No Abstract] [Full Text] [Related]
16. Pharmacological approaches to cystic fibrosis.
Bandiera T; Galietta LJV
Eur J Med Chem; 2021 Apr; 216():113240. PubMed ID: 33691259
[No Abstract] [Full Text] [Related]
17. Cystic fibrosis foundation opens drug discovery lab.
Trivedi BP
Science; 2016 Sep; 353(6305):1194-5. PubMed ID: 27634505
[No Abstract] [Full Text] [Related]
18. New pharmaceutical approaches to the treatment of cystic fibrosis.
Delaney SJ; Wainwright BJ
Nat Med; 1996 Apr; 2(4):392-3. PubMed ID: 8597941
[No Abstract] [Full Text] [Related]
19. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
20. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
